Immuron (IMRN) Total Liabilities (2015 - 2026)
Immuron (IMRN) posted Total Liabilities of $2.0 million for Q3 2026, down 3.6% on a QoQ basis from $2.1 million in Q4 2025, and up 9540.36% year-over-year from $20607.9 in Q3 2025.
Analysis
Immuron (IMRN) Total Liabilities (2015 - 2026) Analysis & Trends
Immuron has reported Total Liabilities for 12 years, with the latest figure at $2.0 million in Q3 2026.
- On a quarterly basis, Total Liabilities rose 9540.36% year-over-year to $2.0 million in Q3 2026; TTM through Aug 2026 was $2.0 million, a 9540.36% increase from a year earlier, with the FY2026 full-year figure at $2.0 million, up 9540.36% from the prior year.
- Total Liabilities was $2.0 million for Q3 2026 at Immuron, down from $2.1 million in the prior quarter.
- The five-year high for Total Liabilities was $2.1 million in Q4 2025, with the low at -$16.1 million in Q3 2022.
- Average Total Liabilities over 5 years is -$1.3 million, with a median of $608752.0 recorded in 2025.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities fell 29.5% in 2025, then soared 9540.36% in 2026.
- Over 5 years, Total Liabilities stood at $12066.4 in 2022, then increased by 27.12% to $15338.6 in 2023, then surged by 7703.14% to $1.2 million in 2024, then soared by 72.18% to $2.1 million in 2025, then declined by 3.6% to $2.0 million in 2026.
- The last three Total Liabilities figures came in at $2.0 million (Q3 2026), $2.1 million (Q4 2025), and $20607.9 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Immuron | 10.53 Mn | 1.51 Mn | - | 1.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Aug 28, 2026 | 1.99 Mn |
| Dec 31, 2025 | 2.06 Mn |
| Sep 2, 2025 | 20,607.86 |
| Jun 30, 2025 | 1.32 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 9, 2024 | 18,927.41 |
| Jun 30, 2024 | 1.87 Mn |
| Dec 31, 2023 | 15,338.64 |
| Sep 28, 2023 | -12.86 Mn |
| Aug 30, 2023 | -196,168.36 |
| Jun 30, 2023 | 1.58 Mn |
| Dec 31, 2022 | 12,066.37 |
| Aug 31, 2022 | -16.12 Mn |
| Jun 30, 2022 | 1.20 Mn |
| Dec 31, 2021 | 8,781.48 |
| Sep 30, 2021 | -19.04 Mn |
| Jun 30, 2021 | 891,761.59 |
| Dec 31, 2020 | -4.13 Mn |
| Sep 1, 2020 | 554,092.00 |
| Jun 30, 2020 | 365,888.56 |